A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33)
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-A33
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 10 May 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Planned End Date changed from 31 Dec 2030 to 30 Apr 2024.
- 18 Dec 2023 Planned primary completion date changed from 30 Jun 2030 to 30 Apr 2024.